Navigation Links
Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
Date:12/6/2012

s being held December 2-6, 2012 in Hollywood, Florida.  For more information, visit www.acnp.org/annualmeeting/default.aspx.

About Naurex
Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor in a safe way.  Naurex's lead product, GLYX-13, has shown promising antidepressant activity with excellent safety in a Phase II trial, confirming the efficacy signals and safety observed in Phase I and preclinical studies.  In a Phase II trial in subjects who had failed treatment with one or more antidepressant agents, a single administration of GLYX-13 produced statistically significant reductions in depression scores within 24 hours, which persisted for an average of seven days.  Naurex's second-generation programs include a number of molecules with preclinical proof of concept.  The company's patented novel chemistry classes represent a platform for the development of new therapies for a variety of CNS disorders.  For more information about Naurex, visit www.naurex.com. Contacts:

MediaNaurex Inc.

BLL Partners, LLCAshish Khanna

Barbara LindheimVice President, Corporate Development

(212) 584-2276(847) 871-0377

blindheim@bllbiopartners.comcorporate@naurex.com
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
8. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
9. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/18/2014)... Dallas, Texas (PRWEB) August 19, 2014 ... China Linalool Industry” is a professional and in-depth ... report provides basic Linalool information, including its ... well as industry overview. This research covers the ... well as global industry analysis covering macroeconomic environment ...
(Date:8/18/2014)... NYElectronic devices with unprecedented efficiency and data ... that use built-in electric polarizations to read ... inside most popular data-driven technology. But ferroelectrics ... blocks, including a curious habit of "forgetting" ... the U.S. Department of Energy,s Brookhaven National ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... Almost by accident, I find myself on what must surely ... the past few months, I have tried the best designs ... I've tried has great strengths and a few tradeoffs, usually ... along comes a Bluetooth wireless headset from a newcomer to ...
... major advantages , ,MADISON, Wis. Wisconsins biotechnology ... feature appearing in the June issue of Modern Drug ... clusters in Madison and Milwaukee, and attributes the growth ... and universities, the Wisconsin Alumni Research Foundation , ...
... lack of funding cited as problems , ,MADISON ... and keep customers happy isnt exactly a revolutionary practice. ... lack funding, even the smallest technological alteration can be ... Matt Miszewski and other speakers described this paradox and ...
Cached Biology Technology:The quest for the perfect headset 2The quest for the perfect headset 3Wisconsin biotech sector featured in scientific magazine 2Wisconsin biotech sector featured in scientific magazine 3State CIO discusses IT and government 2
(Date:8/20/2014)... Aug. 20, 2014 /CNW/ -  Issue ... can quickly become life threatening for some children.    ... 1.2 million Canadians have food allergies and this number may ... of children are estimated to have food allergies.  ... skin irritations and hives to breathing difficulties and loss of ...
(Date:8/20/2014)... Area Lyme Foundation, which aims to make Lyme disease ... research published in an upcoming issue of the Elsevier ... The findings show that ticks that carry Lyme ... making the threat of Lyme disease year-round. The research ... Health (CDPH) Vector-borne Disease Section and University of California, ...
(Date:8/20/2014)... sunscreen and seawater signals a relaxing trip to the ... beach vacation comes with an environmental hitch. When certain ... they can become toxic to some of the ocean,s ... other marine animals. Their study appears in the ACS ... Tovar-Sanchez and David Snchez-Quiles point out that other than ...
Breaking Biology News(10 mins):Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... Wisconsin research team, led by John W. Lough, Ph.D., professor ... stem cells (ES cells) in animals can be cultivated to ... to replace tissue damaged as a result of a heart ... or diseased cells in adult tissues has caused extraordinary interest ...
... Durham, N.C. ?A new understanding of the causes for symptoms ... 600 African-Americans, has resulted from a study by researchers at ... Their findings may lead to a new, more direct method ... that an inability of red blood cells to relax blood ...
... each year worldwide, causing one million deaths. Around 90% ... children. One of the greatest challenges facing Africa in ... chloroquine (CQ), the cheapest and most widely used antimalarial, ... the first-developed and least expensive alternative to CQ, is ...
Cached Biology News:Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks 2Discovery Promises Simpler Therapy for Sickle Cell Disease 2Discovery Promises Simpler Therapy for Sickle Cell Disease 3Reducing malarial transmission in Africa 2
RABBIT ANTI QUINOLINIC ACID...
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
... All MagCellect Ferrofluid products perform ... with R&D Systems MagCellect Magnet. ... this neodymium iron boron permanent ... x 75 mm test tubes ...
Request Info...
Biology Products: